



WHAT DO THESE RESULTS MEAN FOR INDIVIDUALS WITH LOW BODY SURFACE AREA, MODERATE PSORIASIS?

For individuals with low body surface area, moderate psoriasis, the study shows that treatment with **guselkumab** significantly improved their psoriasis. By Week 48, more than 60% of participants achieved meaningful improvements in psoriasis symptoms and quality of life.



WHAT IS THE PURPOSE OF THIS STUDY?

- The purpose of this study is to evaluate the long-term effectiveness of **guselkumab (GUS)** in improving patient-reported outcomes for psoriasis through Week 48.




WHO PARTICIPATED IN THE STUDY AND HOW WAS IT CONDUCTED?

- The study involved 338 patients with psoriasis who were randomly divided into two groups. One group received **guselkumab (GUS)**, and the other received **placebo (PBO)**. The treatment lasted for 48 weeks, with follow-up until week 56.

SPECTREM Study Methods

SPECTREM enrolled people with **moderate plaque psoriasis** affecting 2-15% of their total **body surface area**, with lesions affecting ≥1 high-impact site (scalp, face, skin folds, or genitals) that had failed ≥1 topical therapy

Study Design



Baseline Characteristics

	GUS	PBO
	11.4	11.9
Average DLQI		

DLQI score range, 0-30; scores of 11-20 indicate very large effect of psoriasis on patients' lives

Average Psoriasis Symptoms and Signs Diary (PSSD) Scores at Baseline						
	Itch (0-10)	Pain (0-10)	Stinging (0-10)	Burning (0-10)	Skin Tightness (0-10)	Total Score (0-100)
GUS	6.7	4.8	4.5	4.7	5.9	53
PBO	6.8	4.8	5.0	4.9	6.0	55

DLQI, Dermatology Life Quality Index; GUS, guselkumab; PBO, placebo; PSSD, Psoriasis Symptoms and Signs Diary.

SPECTREM: Effect of Guselkumab on Psoriasis Signs and Symptoms Through Week 48 in Participants with Low BSA, Moderate Psoriasis

April W. Armstrong,¹ Brad P. Glick,² David N. Adam,³ Jennifer Beecker,⁴ Virginie Kelly,⁵ James Krell,⁶ Theodore Alkousakis,⁷ Daphne Chan,⁷ Katelyn Rowland,⁷ Jenny Jeyarajah,⁷ Lorne Albrecht,^{8,9} Richard G. Langley¹⁰

¹Department of Dermatology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; ²Larkin Community Hospital, Miami, FL, USA; ³University of Toronto, Probit Medical Research, and CCA Medical Research, Toronto, ON, Canada; ⁴University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada; ⁵Saint-Louis Medical Clinic, Quebec City, QC, Canada; ⁶Total Skin & Beauty Dermatology Center, Birmingham, AL, USA; ⁷Johnson & Johnson, Horsham, PA, USA; ⁸Enverus Medical Research, Surrey, BC, Canada; ⁹University of British Columbia, Vancouver, BC, Canada; ¹⁰Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, NS, Canada



WHAT WERE THE RESULTS?

The study showed participants experienced significant reductions in symptoms like itching, pain, stinging, and burning, and **more than 33% who received GUS had no symptoms (PSSD=0)** at Week 48

Participants Achieving DLQI of 0 or 1

AT WEEK 16

49% of **GUS-treated** participants achieved **DLQI of 0 or 1** vs **4%** with **PBO**


AT WEEK 48

MORE THAN 60% of participants achieved **DLQI of 0 or 1**



Achievement of DLQI 0 or 1 indicates that psoriasis is not affecting patients' quality of life

Mean PSSD Symptoms Scores



At Week 48, PSSD individual symptom scores were meaningfully improved. More than 3 out of 10 participants receiving GUS achieved a PSSD total symptoms score of 0, indicating a complete absence of itch, pain, stinging, burning, and skin tightness.

Glossary of terms

Psoriasis	A chronic skin condition characterized by red or purple, itchy, and scaly plaques	Placebo (PBO)	A substance with no therapeutic effect used as a control	Dermatology Life Quality Index (DLQI)	A questionnaire used to measure the impact of skin disease on patients' quality of life scored from 0 to 30
Guselkumab (GUS)	An anti-IL-23p19 monoclonal antibody used to treat psoriasis	High-impact sites	Areas of the body such as the scalp, face, skin folds, and genitals. When these areas are affected by psoriasis, the disease often has very large negative effects on patients' quality of life.	Psoriasis Symptoms and Signs Diary (PSSD)	A tool used to measure patient-reported outcomes related to psoriasis symptoms and signs scored from 0 to 100



Scan the QR code for the full poster